SCHEDULE 13G: Schonfeld Strategic Advisors Discloses Significant 7.54% Stake in Applied Therapeutics
Beneficial Ownership Report
Schonfeld Strategic Advisors LLC has reported a 7.54% beneficial ownership stake in Applied Therapeutics, Inc., holding 8,769,640 shares of common stock as of December 31, 2024.
Summary
- Schonfeld Strategic Advisors LLC filed a Schedule 13G with the SEC, disclosing its beneficial ownership in Applied Therapeutics, Inc.
- The filing indicates that Schonfeld Strategic Advisors LLC beneficially owns 8,769,640 shares of Applied Therapeutics, Inc.'s common stock.
- This ownership represents 7.54% of the total outstanding common stock of Applied Therapeutics, Inc.
- The percentage of ownership is calculated based on 116,356,474 shares of common stock outstanding as of November 6, 2024, as reported by Applied Therapeutics in its Quarterly Report on Form 10-Q.
- Schonfeld Strategic Advisors LLC, an investment adviser, states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive as it indicates a significant institutional investment in the company, which can be perceived as a vote of confidence. However, it's a factual disclosure rather than a performance report, so the positive impact is indirect.
Positives
- Significant institutional investment: Schonfeld Strategic Advisors, a notable investment adviser, has taken a substantial 7.54% stake in Applied Therapeutics, which could be viewed as a vote of confidence from a sophisticated investor.
- Passive investment: The filing indicates the stake was acquired in the ordinary course of business and not for the purpose of influencing control, suggesting a long-term, non-activist investment perspective.
Future Outlook
NA
Industry Context
This filing represents a routine disclosure of significant passive institutional ownership, common in the financial industry for investment advisers managing private funds. It indicates that a notable investment firm has taken a substantial position in Applied Therapeutics, Inc., a biotechnology company, which is a standard practice for institutional investors seeking exposure to specific sectors or companies.
Comparison to Industry Standards
- This document is a disclosure of beneficial ownership by an investment adviser and does not contain performance metrics or operational results that can be directly compared to industry standards for companies like Applied Therapeutics.
- The ownership percentage of 7.54% is a significant stake for an institutional investor, indicating a notable position in the company's equity.
Stakeholder Impact
- Shareholders: May view the significant stake by Schonfeld Strategic Advisors as a positive signal, potentially increasing investor confidence and attracting further institutional interest.
Key Dates
| Date | Description |
|---|---|
| 2024-11-06 | Date as of which 116,356,474 shares of common stock were outstanding, as reported in Applied Therapeutics' Form 10-Q. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 2025-02-14 | Date of filing of the Schedule 13G statement. |
Keywords
Applied Therapeutics, Schonfeld Strategic Advisors, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Adviser, ATLX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.